Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label, Sequential Dose-Escalation, Safety, Tolerability and Efficacy Study of SIG-005 in Adult Patients With Mucopolysaccharidoses 1 (MPS-1)

NCT05665036 is registered in ClinicalTrials.gov with Sigilon Therapeutics, Inc. as lead sponsor.

NCT NCT05665036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05665036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label, Sequential Dose-Escalation, Safety, Tolerability and Efficacy Study of SIG-005 in Adult Patients With Mucopolysaccharidoses 1 (MPS-1)
Lead sponsor
Sigilon Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
November 15, 2021
Completion date
December 13, 2022
Enrollment
0 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

mps i, mps1-hs, mps1-s